More evidence. More confidence. More successful outcomes.
Discover our endovascular solutions at the LINC 2023 Congress, a renowned gathering of healthcare professionals from around the world!
Find out our endovascular cutting-edge scientific activities through our global team of experts, committed to unlocking life-changing outcomes for patients.
Join the online conversation and use #LINC2023
Join the conversation with our global panel of professionals, who will share their knowledge and perspectives on the latest evidence on the fight against Peripheral Artery Disease (PAD).
Chairs: Prof. Brodmann and Prof. Deloose
Prof. Brodmann: RCT data, the pinnacle of proof
Prof. Torsello: Real world data
Dr. Iida: Real world data from Japan
Prof. Gouëffic: Big data from big databases
All: Where we have been, what we have learnt, where we are going
Live Case Session
Occlusive disease in the Superficial Femoral Artery (SFA) remains challenging because of the high rates of restenosis8. Restenosis following SFA treatment is prevalent and depends on the choice of therapy.
Boston Scientific offers the only drug-eluting technologies backed by 5 RCTs, and studies that will exceed 10,000 patients1-6 Our SFA portfolio includes all the devices needed to access, prepare and treat any type of lesion.
The advanced technologies of drug-coated balloons and drug-eluting stents have been proven to lower the risk of restenosis compared to non-drug devices2,7 enabling to optimise outcomes for patients.
Sachar R et al. RANGER II SFA Investigators. 1-year results from the RANGER II SFA randomized trial of the Ranger drug-coated balloon. JACC Cardiovasc Interv. 2021;10:1123–1133.
Gouëffic Y, et al. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: Primary results of the EMINENT randomized trial. Circulation. 2022;146:1564–1576.
Steiner S, et al. 12-month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment. JACC Cardiovasc Interv. 2018;11:934–941.
Steiner S, et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J. 2020;41:2541–2552.
Müller-Hülsbeck S, et al. Two-year efficacy and safety results from the IMPERIAL Randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44:368–375.
Marianne Brodmann, CIRSE 2022 Symposium: DET in complexities co-morbidities, and underserved patient populations.
Ullah W, et al. Safety and efficacy of drug-coated balloon for peripheral artery revascularization-A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2022;99(4):1319–1326.
Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M et al; Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: Circ Cardiovasc Interv. 2010 Jun 1; 3(3): 267-276. doi: 10.1161/CIRCINTERVENTIONS.109.903468
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.